Bridget Cole, Ph.D. Email & Phone Number

Boston, Ma, Us

Boston, Massachusetts, United States

Boston, Massachusetts, United States

1910 Genetics is a biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI with three proprietary data streams – computational data, wet lab proxy biological data, and wet lab ground truth biological data – to deliver novel drug candidates and software solutions to leading pharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer. Our vision is to make undruggable targets a thing of the past.

Waltham, Massachusetts, United States

Cambridge, Ma

Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons. For more information, visit: www.nociontx.com.

Greater Boston Area

Charlestown, Ma

As the Vice President of R&D Chemistry, I managed the cGMP manufacture of CFTR corrector FDL169 drug substance and drug product to support the phase-1 clinical trial in addition to leading medicinal chemistry research to deliver clinical development candidate FDL176, which is a CFTR potentiator.

Flatley Discovery Lab is an independent not-for-profit research organization focused on discovering small molecules that restore ΔF508-CFRT protein function to treat Cystic Fibrosis. As the head of Chemistry I built up the chemistry resources at FDL while leading the main research program from HTS through to nomination of clinical development candidate candidate FDL169. As a key member of the leadership team my responsibilities included medicinal chemistry, CMC, CTM, DMPK and toxicokinetics.

As the head of Discovery my staff and I conducted novel research and supported development of three clinical candidates. I closely directed medicinal chemistry in addition to managing bio-analytical analysis of plasma/tissue samples, in vivo pharmacology, ADME research and some in vitro biology. Using WinNonlin modeling software I performed pharmacokinetic and toxicokinetic analyses to support in vivo discovery, preclinical toxicology and human clinical studies.

As Vice President of Chemistry I directed medicinal chemistry research to identify novel back-up molecules to three clinical assets in addition to initiating new research programs that have yielded novel lead molecules with desired in vivo pharmacology to establish proof of concept for those programs. Working closely with my team we enhanced surface chemistries for our SAM-based technology platform and have presented our results externally at regional and national ACS meetings.

Consultant for drug discovery services.

As an Associate Director I managed a diverse group of scientists responsible for hit to lead medicinal chemistry, high throughput purification of SAR compounds, chemistry technology projects and QC of screening plates and liquid compound files

As a Senior Principal Scientist I was a founding member of the Cambridge Chemistry group. My team and I discovered a series of novel 11bHSD-1 inhibitors for the treatment of type-2 diabetes.

As Project Leader I led a group of medicinal chemists working on the development of novel GPCR ligands for the treatment of metabolic disorders.

As Senior Research Scientist I conducted research that identified novel Melanocortin receptor-IV ligands.

As a Research Scientist I developed enterocyte-selective MTP inhibitors for the treatment of obesity and made significant SAR contributions to the discovery of the marketed drug Slentrol.

Postdoctoral Research Fellow, Chemistry

Ph.D., Chemistry

Bachelor'S Degree, Chemistry